Avasimibe

CAS: 166518-60-1

Ref. 3D-RGA51860

Informação sobre produto

• Nome: Avasimibe
• Sinónimos: ((2,4,6-Tris(1-Methylethyl)Phenyl)Acetyl)Sulfamicacid2,6-Bis(1-Methylethyl)Phenylester, 2,6-Di(Propan-2-Yl)Phenyl {[2,4,6-Tri(Propan-2-Yl)Phenyl]Acetyl}Sulfamate, 2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)acetyl)sulfamate, Avasimin, Ci 1011, N-(2,6-Dipropan-2-Ylphenoxy)Sulfonyl-2-(2,4,6-Tripropan-2-Ylphenyl)Acetamide, N-[(2,6-Diisopropylphenoxy)Sulfonyl]-2-(2,4,6-Triisopropylphenyl)Acetamide, Pd 148515, Sulfamic acid, N-[2-[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester, Sulfamic acid, [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester

Descrição

Avasimibe is a drug that inhibits the enzyme DPP-IV and prevents the degradation of DPP-IV substrates, such as peptides, proteins, and lipids. It also has other pharmacological effects such as inhibiting the mitochondrial membrane potential and inducing cell lysis. Avasimibe is used to treat atherosclerosis by preventing cholesterol from being absorbed by cells. It is also used in cancer treatment for its ability to inhibit viral life and reduce tumor size. In addition, avasimibe is able to inhibit BCR-ABL kinase activity and induce apoptosis in human leukemia cells.

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 501.72 g/mol
• Fórmula: C₂₉H₄₃NO₄S
• Pureza: Min. 95%
• Cor/forma: Powder